Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ATAI Life Sciences N.V. - Common Shares
(NQ:
ATAI
)
1.410
-0.100 (-6.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,283,097
Open
1.500
Bid (Size)
1.380 (2)
Ask (Size)
1.420 (50)
Prev. Close
1.510
Today's Range
1.385 - 1.540
52wk Range
1.030 - 2.850
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Study Finds That Bad Psychedelic Trips Double Some Individuals’ Fatality Risk
March 05, 2025
Via
Investor Brand Network
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
March 05, 2025
From
atai Life Sciences
Via
GlobeNewswire
Performance
YTD
-11.88%
-11.88%
1 Month
-36.49%
-36.49%
3 Month
-11.32%
-11.32%
6 Month
+13.71%
+13.71%
1 Year
-30.20%
-30.20%
More News
Read More
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
February 20, 2025
From
atai Life Sciences
Via
GlobeNewswire
Veterans Turn to One Another for Help Using Psychedelics to Combat Mental Health Challenges
February 19, 2025
Via
Investor Brand Network
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
February 14, 2025
Via
Stocktwits
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 13, 2025
Via
Benzinga
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
February 13, 2025
Via
Benzinga
atai Life Sciences Announces Pricing of Public Offering of Common Shares
February 12, 2025
From
atai Life Sciences
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
February 12, 2025
Via
Chartmill
atai Life Sciences Announces Proposed Public Offering of Common Shares
February 12, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
January 28, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
January 10, 2025
From
atai Life Sciences
Via
GlobeNewswire
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
November 15, 2024
Via
Investor's Business Daily
Topics
Government
Exposures
Political
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
November 13, 2024
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
November 13, 2024
Via
Benzinga
Exposures
Product Safety
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 13, 2024
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
October 15, 2024
From
atai Life Sciences
Via
GlobeNewswire
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
October 07, 2024
Via
Benzinga
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
October 04, 2024
Via
Benzinga
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
September 15, 2024
Via
Talk Markets
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
September 12, 2024
Via
Benzinga
Exposures
Product Safety
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
September 10, 2024
Via
Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
September 06, 2024
Via
Talk Markets
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.